LTRNライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process...

Stats
本日の出来高	128 678
平均出来高	319 038
時価総額	59.08M
EPS	$0 ( 2024-03-18 )
次の収益日	( $-0.400 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.74
ATR14	$0.0370 (0.68%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-27	Fletcher Aaron G.l.	Sell	34 731	Common Stock
2024-02-28	Fletcher Aaron G.l.	Sell	51 608	Common Stock
2024-02-29	Fletcher Aaron G.l.	Sell	13 686	Common Stock
2024-02-27	Fletcher Aaron G.l.	Sell	10 620	Common Stock
2024-02-28	Fletcher Aaron G.l.	Sell	15 780	Common Stock

INSIDER POWER
-62.96
Last 98 transactions
Buy: 4 152 509 \| Sell: 1 662 260

ボリューム相関

長: 0.26 (neutral)

短: -0.72 (moderate negative)

Signal:(31.755) Neutral

Lantern Pharma Inc. 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Lantern Pharma Inc. 相関 - 通貨/商品

-0.23
( neutral )

-0.16
( neutral )

0.00
( neutral )

-0.43
( neutral )

-0.05
( neutral )

0.25
( neutral )

Lantern Pharma Inc. 財務諸表

Annual	2023
収益:	$0
総利益:	$-174 843 (0.00 %)
EPS:	$-1.470

FY	2023
収益:	$0
総利益:	$-174 843 (0.00 %)
EPS:	$-1.470

FY	2022
収益:	$0
総利益:	$-154 681 (0.00 %)
EPS:	$-1.300

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.105

Financial Reports:

No articles found.

Lantern Pharma Inc.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.